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KAJIAN ANTIDIABETIK DAN TOKSIKOLOGI EKSTRAK GONGRONEMA 
LATIFOLIUM 
ABSTRAK 
Gongronema latifolium Benth. (Apocyanaceae) (GL) mempunyai aktiviti 
menurunkan glukosa yang berpotensi untuk digunakan secara meluas. Kajian ini 
mengkaji kesan antidiabetik dan toksik GL. Etanol dan peralatan Soklet digunakan 
untuk mendapatkan ekstrak soklet etanolik GL (GLES) daripada daunnnya. Bagi 
mengkaji kesan antidiabetik, GLES diberikan secara oral kepada tikus – tikus jantan 
Sprague-Dawley (SD) yang normal dan diabetik aruhan STZ. Aras glukosa darah 
(BGLs), profil lipid serum, aras insulin dan pankreas dinilai selepas rawatan selama 14 
hari. Bagi menilai ketoksikan GL, GLES diberikan secara oral pada dos 250, 500, dan 
1000 mg/kg kepada tikus – tikus SD selama 90 hari berdasarkan garis panduan OECD. 
Indeks ketoksikan yang diukur, termasuk berat badan, parameter – parameter biokimia 
dan hematologi, dan berat organ – organ penting. Penilaian histopatologi bagi organ – 
organ penting yang terlibat dalam metabolisma xenobiotik dan perkumuhan – hati dan 
ginjal – juga dijalankan. GLES menurunkan BGLs tikus normal secara signifikan (P < 
0.05) dalam ujian toleransi glukosa pada dos 2 g/kg berat badan, tetapi gagal 
merekodkan kesan yang sama pada tikus diabetik dalam rawatan akut selama 7 jam. 
Rawatan dengan 1 g/kg berat badan, dua kali sehari mengawal BGLs secara sederhana 
seawal hari kesepuluh. Selepas 14 hari rawatan, 1 g/kg dan 0.5 g/kg berat badan GLES 
menyebabkan peningkatan dalam purata luas kawasan Langerhans islet, masing – 
masing sebanyak 44% dan 50% dibandingkan dengan DC. Dengan menggunakan otot 
abdominal tikus, GLES dikesan bertindak sebagai penggalak insulin yang sederhana. 
Analisis GC-MS menunjukkan kehadiran Sitostenon, komponen fitosterol yang 
diketahui mampu menurunkan glukosa. Dalam kajian toksisiti, GLES tidak 
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menunjukkan sebarang kesan signifikan terhadap panel – panel fungsi ginjal dan hati, 
dan parameter hematologi yang diukur. Trigliserida serum, jumlah kolesterol dan 
lipoprotein ketumpatan rendah mencatatkan penurunan di dalam tikus jantan seiring 
dengan pengurangan dalam pengumpulan lemak badan retroperitoneal (P < 0.05). 
Terdapat percanggahan yang signifikan antara berat organ pada dos yang paling tinggi. 
Sebagai contoh, hati menunjukkan pembesaran secara signifikan pada kedua – dua 
jantina (P < 0.05). Walaubagaimanapun, kajian histopatologi tidak menunjukkan 
sebarang lesi patologi pada hati mahupun ginjal. Secara keseluruhannya, penggunaan 
GL dalam mengawal DM menunjukkan kesan yang setara dengan ubat antidiabetik oral 
konvensional dan ia mengandungi struktur penyembuhan terhadap pankreas, mungkin 
disebabkan oleh kehadiran Sitostenon dan komponen bukan fenolik yang lain. Di 
samping itu, kajian ini telah mengesahkan bahawa pengambilan GL secara jangka 
panjang adalah selamat, sama ada sebagai sayuran, herba mahupun untuk tujuan 
perubatan; tetapi tidak pada dos yang sangat tinggi melebihi tempoh masa tertentu.   
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ANTI-DIABETIC AND TOXICOLOGICAL STUDIES OF GONGRONEMA 
LATIFOLIUM 
ABSTRACT 
Gongronema latifolium Benth. (Apocyanaceae) (GL) possesses a considerable 
glucose lowering activity to be utilized on a large-scale. This study investigates the 
antidiabetic and toxic effects of GL. Ethanol and a Soxhlet apparatus were used to 
obtain GL ethanolic Soxhlet extract (GLES) from the leaves. To examine the 
antidiabetic effect, GLES was orally administered to male Sprague-Dawley (SD) 
normal and STZ-induced diabetic rats. Blood glucose levels (BGLs), serum lipid 
profile, insulin levels and the pancreas were evaluated after 14 days of treatment. To 
assess GL toxicity, GLES was administered orally at 250, 500 and 1000 mg/kg to SD 
rats for 90 days following OECD guidelines. Toxicity indices were measured, including 
body weight; biochemical, and hematological parameters; and weights of vital organs. 
Histopathological assessment of the key organs involved in xenobiotic metabolism and 
excretion – liver and kidneys - was conducted. GLES significantly (P < 0.05) decreased 
BGLs of normal rats in glucose tolerance testing at a dose of 2 g/kg b.w., but failed to 
do so in diabetic rats undergoing acute 7-h treatment. Treatment with 1 g/kg b.w. twice 
daily moderately controlled diabetic BGLs starting from day 10. After 14 days of 
treatment, 1 g/kg and 0.5 g/kg b.w. of GLES caused 44% and 50% respective increases 
in the average area of Langerhans islets compared to DC. Using isolated rat abdominal 
muscle, GLES was found to be a mild insulin-sensitizer. GC-MS analysis revealed the 
presence of known glucose-lowering phytosterol, Sitostenone. In the toxicity study, 
GLES did not exert a significant effect on measured liver and kidney function panels, 
and hematological parameters. Serum triglycerides, total cholesterol and low density 
lipoproteins were decreased in the male rats along with depletion in retroperitoneal body 
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fat depots (P < 0.05). Significant organ weight discrepancies were observed at the 
highest dose. For instance, the liver was significantly enlarged in both sexes (P < 0.05). 
However, histopathological studies did not show any pathological lesions in the liver or 
the kidneys. Overall, GL use in DM management was found to be comparable to a 
conventional oral antidiabetic drug and precipitate structural recovery in the pancreas, 
probably due to Sitostenone and other non-phenolic components. Furthermore, this 
work validated the safety of GL long-term use as a vegetable, spice and for medicinal 
purposes; but not at very high doses over an extended period of time.  
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CHAPTER ONE: INTRODUCTION 
 
1.1 Diabetes overview  
Diabetes mellitus (DM) is a heterogeneous metabolic disorder characterized by altered 
carbohydrate, lipid, and protein metabolism causing hyperglycemia, which results from 
insufficient insulin secretion, insulin action or both (Joseph and Jini, 2011; Mutalik et 
al., 2003). Loss of control over blood glucose homeostasis is DM’s main feature, which 
is attributed either to insulin deficiency or to insulin resistance— hence, the etiologic 
classification: Type I DM and Type II DM. The World Health Organization (WHO) 
projects that DM will become the 7th leading cause of death in the world in 2030. The 
state of chronic hyperglycemia and abnormal metabolism of nutrients which 
accompanies DM leads to severe consequences on one’s wellbeing if not properly 
managed, such as retinal bleeding, nerve damage, renal failure, and immunity 
depression (Vivek et al., 2010). Unfortunately, increasingly ageing populations 
worldwide, consumption of calorie-rich diets, obesity, and sedentary lifestyles have led 
to a tremendous increase in the number of diabetics in the past century (Rao and 
Subramanian, 2009).  
 
1.1.1 Terminology 
Diabetes as a term was used for the first time by the Greek doctor Aretaeous of 
Capadocia in the 2
nd
 century AD. Diabētēs was derived from the verb diabainein, which 
is made up of the prefix dia-, "across/apart" and the word bainein, "to walk/stand”. The 
word “diabetes” translates into “to pass through”, which probably referred to one of the 
main manifestations of the disease, excessive urination; which is accompanied by 
failure to achieve satiety with eating, and recurring thirst (MacFarlance et al., 1997). 
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“Mellitus” was added centuries later by the English physician John Rollo in the 18th 
century AD to reflect the glucose-containing nature of the urine excreted by those 
inflicted with the condition i.e., glycosuria. Hence, mellitus, which is a word of a Latin-
Greek origin that denotes honey, served the purpose of distinguishing “diabetes 
mellitus” from other polyuric conditions (Rollo, 1797), mainly diabetes insipidus 2013).  
 
1.1.2 Classification 
There are two chronic types of DM: Type I, which is more sever, describes a condition 
in which insulin secretion is completely absent due to immune destruction of pancreatic 
β-cells (i.e., Insulin-Dependent Diabetes Mellitus: IDDM), whereas Type II describes a 
condition in which bodily cells (other than neurons) become irresponsive to insulin (i.e., 
Non-Insulin-Dependent Diabetes Mellitus: NIDDM). Gestational diabetes mellitus 
(GDM) is another common non-chronic class of DM that can occur during pregnancy. 
IDDM patients rely on insulin injections or pumps for treatment, which poses risks of 
ketosis and coma associated with overdosing (ADA, 2005). Patients of Type II DM 
make nearly 90% of the global diabetic population; and treatment for type II DM, a 
multifactorial disease, includes many different, expensive combinations of drugs whose 
use is restricted by their pharmacokinetic properties, secondary failure rates, and many 
accompanying side effects (Hammouda and Amer, 1966), which include weight gain, 
increased risk of hypoglycemia, and increased risk of mortality (Rang and Dale, 1999). 
 
1.1.2.1 Insulin-Dependent Diabete Mellitus (IDDM)  
IDDM, Type 1 DM, is a chronic disorder caused by immune destruction of β-cells in the 
pancreas, leading to insulin deficiency and hyperglycemia (Van Belle et al., 2011). 
Chronic hyperglycemia results in long-term damage, dysfunction, and failure of several 
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tissues and organs, including the eyes, kidneys, nerves, heart, and blood vessels 
(Mellitus, 2005). IDDM has been linked to increased risk of microvascular and 
neurological complications (Control and Trial, 2005). IDDM incidence features an onset 
of weight drop, excessive thirst, urination, and polyphagia (Van Belle et al., 2011). 
Management of IDDM necessitates regular insulin parenterals on daily basis, self-
monitoring of BGLs, and the calorie values of foods (Loghmani, 2005). Treatment for 
IDDM is risky. Insulin injections are associated with increased risk of fatal 
hypoglycemia (Van den Berghe et al., 2006) and although the use of insulin pumps can 
reduce the risk of treatment-elicited hypoglycemia (Boland et al., 1999), the side effects 
of regular insulin intake, such as weight gain, and the daily dependence on insulin 
preparations is far from convenient.  
 
1.1.2.2 Non-Insulin-Dependent Diabetes Mellitus (NIDDM) 
NIDDM, Type 2 DM, is underlined by a spectrum of etiologies, ranging from 
predominant insulin resistance and relative impaired insulin secretion to predominant 
impaired insulin secretion coupled with relative insulin resistance (Mellitus, 2005). This 
makes treatment a kind of trial-and-error, particularly upon initiation (Genuth et al., 
2003). Impaired insulin action often underlies a deficiency in several molecules 
involved in insulin signaling pathways (ADA, 2014). NIDDM diabetic population 
represents over 90% of the world diabetic burden. Alarmingly, epidemiological data 
indicates that about 50% of those inflicted with NIDDM are actually undiagnosed 
(Rosenbloom et al., 1999). The risk factors for developing NIDDM include rampant 
obesity, aging, lack of exercise, genetic predisposition and ethnicity (Loghmani, 2005). 
Genetic predisposition, obesity and a sedentary lifestyle stand out as the major factors 
associated with the onset of NIDDM in adults (Hauner and Scherbaum, 2002). The 
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United Kingdom Prospective Diabetes Study (UKPDS) described NIDDM as a 
progressive disorder that is initially manageable with one oral hypoglycemic drug, but 
that ultimately calls for the addition of other medications (DeFronzo, 1999). 
Management of this disorder later in life will require the administration of several 
hypoglycemic agents. However, available NIDDM drugs have been known to vary in 
their pharmacokinetic properties and cause a spectrum of side effects (Hammouda and 
Amer, 1966), including weight gain and hypoglycemia (Rang and Dale, 1999). Yet, 
medical practitioners advise the inclusion of complex drug regimens for the 
management of NIDDM to avoid its morbid complications. 
 
1.1.2.3 Gestational Diabetes Mellitus (GDM) 
GDM is a form of DM that may be experienced by some pregnant women. Women who 
are diagnosed with GDM usually presenting with elevated BGLs, serum insulin levels, 
exaggerated insulin spike upon food consumption, and blunted intravenous insulin 
responses (Carpenter and Coustan, 1982; WHO, 1980). The condition is commonly self-
limiting. However, a significant adverse outcome may happen when GDM coincides 
with rampant obesity (Catalano et al., 2012). A vigorous treatment regimen is necessary 
in such cases and evidence indicates marked risk reduction with such regimens (Langer 
et al., 1994). If symptoms of GDM do not subside after child birth, which occurs in 
some scenarios, the diagnosis is changed to NIDDM and treatment is adjusted 
accordingly (ADA, 2005). 
 
1.1.3 Classes of conventional hypoglycemic agents 
DM medications are pharmacologically classified as inulinotropic agents (or 
secretogoges), insulin sensitizers, glucose absorption down-regulators, glucose 
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excretion inducers and hormone analogs. From a chemical perspective, as of 2014, ten 
classes of hypoglycemic agents have been employed for the management of elevated 
BGLs in DM patients. They include insulin analogs, pramlintide (amylin analog), 
biguanides (metformin), sulfonylureas, glinides, α-glucosidase inhibitors, 
thiazolidinediones, DPP-4 inhibitors, GLP1 Receptor agonists, and SGLT2 inhibitors. 
As evident from several surveys, Metformin has been the agent of choice for the 
treatment of NIDDM, followed by sulfonylureas, thiazolidinediones, DPP-inhibitors 
and α-glucosidases inhibitors as monotherapy or in combination (Alam et al., 2014; 
Sharma et al., 2016), whereas insulin replacement therapy has been the standard 
approach for the management of IDDM. 
 
1.1.3.1 Insulin-replacement therapy 
Insulin is a product of β-cells whose level increases in the blood following meals to 
ameliorate elevated BGLs. It is the agent of choice for the treatment of IDDM. 
However, the UK Prospective Diabetes Study Group propose that NIDDM patients 
ought to require the administration of insulin over the course of the disease (UKPDS, 
1998). Synthetic human insulin analogues have been utilized for years, differing mainly 
in their onset of action. Recently, the patents of many known insulin analogs expired, 
and some are about to (insulin lispro, 2013; insulin glargine, 2014–2015; insulin aspart, 
2017) (Rotenstein et al., 2012), which should make way for pharmaceutical companies 
to develop biosimilar products freely in the near future. Owing to the lower cost of these 
alternatives, non-traditional insulin products have already spread in China, India, 
Pakistan, Thailand, Peru, and Mexico (Polimeni et al., 2015). The main shortcoming of 
insulin preparations is the fact that insulin degrades in the GI tract, making its use as an 
injection an inconvenient necessity. This continues to put IDDM at high risk of adverse 
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reactions as the drug reaches the blood stream rapidly by subcutaneous injection 
(Nathan et al., 2009). 
 
1.1.3.2 Pramlintide 
 Pramlintide is an FDA approved synthetic analogue of amylin that is administered 
parenterally. The use of this hormonal analog started in 2005 as an adjunctive therapy 
with regular and rapid-acting insulins. Amylin is secreted by the pancreas after meals to 
regulate BGLs. It delays glucose absorption at the level of the intestine and suppresses 
glucagon. Concomitant administration of both pramlintide and insulin was reported to 
better control BGLs and body weight in NIDDM patients (Hollander et al., 2003). 
However, like all new drugs, pramlintide is still relatively costly. Moreover, its safety 
has not yet been established (Nathan et al., 2009). Studies have shown the use of 
pramlintide to cause adverse gastrointestinal effects (Riddle et al., 2007).  
 
1.1.3.3 Metformin 
Metformin was derived from Guanidine, a secondary metabolite of a Europe-native herb 
called Galega officinalis. The use of this herb for the management of DM can be traced 
back to medieval Europe (Panzram, 1987). Metformin is considered a great example of 
a widely used medication derived from nature in 1957 (Luft et al., 1978). It belongs to 
the biguanides family, of which metformin has been the only available member since 
the 1970s (Song, 2016). For years it was classified as an insulin sensitizer that lowered 
BGLs primarily by reducing hepatic glucose output and increasing cells’ response to 
insulin. However, very recently the systemic effect of metformin was shown to be 
inferior to its main action on the distal part of the GI tract (Buse et al., 2016). Although 
the mechanism of action of metformin has not been fully elucidated yet, it was reported 
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as the most prescribed drug for NIDDM in 2016 (Sharma et al., 2016). It is available as 
a monotherapy and in combinations (Bailey, 1992). Metformin is also the drug-of-
choice for diabetics with large waist circumferences and is preferred over sulfonylureas 
and insulin preparations in this patient category to avoid weight increments and 
hypoglycaemic events (Campbell et al., 1996). It was also shown to enhance the lipid 
profile in NIDDM patients (DeFronzo et al., 1991). Despite being considered safe and 
effective, metformin use is associated with gastrointestinal disturbance (Nathan et al., 
2009). Moreover, its use is not recommendable in a good proportion of NIDDM patients 
who suffer from renal complications (Kramer et al., 2003).  
 
1.1.3.4 Sulfonylureas 
Sulfonylureas are hypoglycemic agents classified as insulin secretogogs. Examples 
include glibenclamide, also known as glyburide; tolbutamide; chlorpropamide; 
glipizide; gliclazide; and glimpepiride (Rosskamp, 1996), which is the most prescribed 
drug of this class (Sharma et al., 2016). Intensive administration of a sulfornylurea in 
NIDDM patients is comparable to insulin intensive therapy in terms of decreasing the 
risk of nephropathy, retinopathy, and neuropathy (UKPDS, 1998). On the other hand, 
the side effects of progressive use include weight increment and potentially-fatal 
hypoglycemia (Nathan et al., 2009). This drug class is also associated with adverse 
cardiovascular events (Evans et al., 2006) due to lack of specificity because cardiac 
myocytes express the same sulphonylurea receptor as pancreatic β-cells. 
 
1.1.3.5 Metiglinides 
Metglinides (glinides) share the same mechanism of action with sulfonylureas. 
Examples include repaglinide and nateglinide. Both glinides and sulfonylureas block 
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potassium channels associated with the sulfonylurea receptor to increase serum insulin 
levels. However, a glinide binds to a different site as compared with a sulfonylurea 
(Malaisse, 2003). They are extremely effective agents that have been successful in 
managing DM in patients who are irresponsive to other treatments (Füchtenbusch et al., 
1999). They are safer than sulfonylureas (Damsbo et al., 1999). However, glinides are 
considered a costly option. To make things worse, they necessitate multiple doses 
during the day because of  their short half-lives (Nathan et al., 2009). Furthermore, 
glinides practically cause the same unwanted body weight increment as sulfonylureas in 
NIDDM patients.   
 
1.1.3.6 α-Glucosidase Inhibitors 
Alpha-glucosidases are enzymes in the small intestine responsible for the breakdown of 
starch and sucrose. Examples include acarbose and miglitol. These antidiabetic agents 
target the gastrointestinal absorption of carbohydrates in the small intestine and result in 
prolonged absorption, which effectively blunts the postprandial spike in BGLs (Ron et 
al., 2002). Alpha-glucosidase inhibitors do not cause fatal hypoglycemia or weight 
loss/gain (Nathan et al., 2009). They are also advantages over other treatments because 
they facilitate the body to respond to food intake with lower levels of insulin 
(Rosskamp, 1996). The use of acarbose, in particular, is associated with a lower risk of 
cardiovascular disease and hypertension (Chiasson et al., 2003). Unfortunately, at the 
beginning of treatment, this drug class causes flatulence and diarrhea as seen in those 
suffering from lactose (Swagerty Jr et al., 2002). This embarrassing side effect leads a 
large number of diabetics to discontinue the medication. 
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1.1.3.7 Thiazolidinediones 
Thiazolidinediones (TZDs), also referred to as glitazones, are synthetic hypoglycemic 
and antihyperglycemic agents that act both as insulin sensitizers and as insulin 
mimickers by induction of the peroxisome proliferator activated nuclear receptor 
(PPARϒ) (Day, 1999). Two of the most common glitazones are rosiglitazone and 
pioglitazone. When used concomitantly with metformin, rosiglitazone achieves better 
glycemic control (Khan et al., 2016). However, it may illicit adverse cardiovascular 
complications and more weight gain than some sulfonylureas (Kahn et al., 2006). 
Moreover, a considerable number of health agencies have either totally banned or 
cautioned against the administration of pioglitazone in NIDDM patients following 
reports of medication-elicited bladder cancer (Sharma et al., 2016).  
 
1.1.3.8 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors 
DDP-4 is an enzyme responsible for the rapid removal of incretins, insulinotropic 
peptides that are secreted to help ameliorate the rise in postprandial BGLs and reduce 
the rate of glucagon secretion. Consequently, DPP-4 inhibiting agents exert their 
hypoglycemic effect in an incretin-like mechanism (Takahashi et al., 2015) by 
increasing GLP-1 levels, a natural incretin (Nauck, 2011). Examples include sitagliptin 
and vildagliptin. These medications were reported to decrease elevated BGLs as 
effectively as metformin (Migoya et al., 2010) and lower HbA1c by 0.5–1.0% without 
causing significant adverse effects or weight increment (Drucker and Nauck, 
2006). Nevertheless, the long-term safety of DDP-4 inhibitors has not been established 
(Nathan et al., 2009). They are classified as non-selective agents because the DDP-4 
enzymes are expressed all around the body, including immune cells. 
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1.1.3.9 GLP-1 Receptor Agonists 
Glucagon-Like Peptide 1 (GLP-1) is a product of intestinal cells that increases the level 
of circulating insulin. The use of a GLP-1 receptor agonist – named exendin-4 and 
exenatide – was officiated in 2005 by the FDA in combination with metformin, 
sulfonylureas and TZDs. Exenatide suppresses gastric motility and glucagon secretion 
(Nathan et al., 2009). Reports linked its use to mild to moderate gastrointestinal side 
effects, including vomiting and diarrhea (DeFronzo et al., 2005). However, as an 
adjuvant, metformin can help ameliorate these unwanted adverse effects (Thong et al., 
2015). Yet, alarmingly, a recent report linked exenatide to the incidence of pancreatitis 
in NIDDM patients (Monami et al., 2014).  
 
1.1.3.10 SGLT2 inhibitors 
This is the newest class of the antihyperglycemic agents available. Inhibitors of 
Sodium–Glucose co-Transporters (SGLTs) (current example: Dapagliflozin) were 
approved for use as monotherapy and in combination with classical antidiabetic 
medications in 2014. These agents increase the execration of glucose in the urine and 
were shown to decrease BGLs remarkably, even when administered as monotherapy, 
without serious side effects (Chao and Henry, 2010). Nevertheless, this therapeutic 
approach might illicit unwanted urinary tract infections and general lack of energy 
because of the glucose shed with the urine.   
 
1.1.4 Diagnosis 
A person is said to suffer from DM when he/she has symptoms of diabetes (polyuria, 
polydipsia, and unexplained weight loss) and shows a plasma glucose level of 200 
mg/dl (11.1 mmol/l) or above at any time of the day. The diagnosis can also be DM if a 
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patient had BGLs of 126 mg/dl (7.0 mmol/l) while fasting, which is defined as no 
caloric intake for at least 8 h (ADA, 2005). 
 
1.1.5 Worldwide burden   
In the year 2000, DM cases worldwide reached 171 million. This number was expected 
to double in thirty years, regardless of the prevalence of obesity, a major risk factor of 
DM, remaining stable or not (Sarah et al., 2004). Yet, only ten years later, an estimated 
285 million people worldwide had diabetes mellitus (Shaw et al., 2010). This made DM 
one of the most immanent public health challenges to all nations. A few decades ago, 
NIDDM was relatively rare in developing countries, but recently, developing countries 
have suffered the major burden of diabetes mellitus (Chen et al., 2012). Sadly, probably 
due to inferior health care systems, 80% of diabetes deaths occur in low- and middle-
income countries (WHO). The problem is continuously aggravating as the number of 
diabetics in the countries of the Western Pacific Region is expected to double within the 
next twenty years (Whiting et al., 2011).  
 
1.1.6 Malaysian Burden 
In the period between the years 1996-2006, the incidence of diabetes in Malaysia 
increased by 80%. Furthermore, the number of obese Malaysian adults, who are at high 
risk of developing DM, was estimated at 14% of the population in 2006, owing to an 
increased daily consumption of sugar and a sedentary life style (Institute for Public 
Health, Health Ministry of Malaysia). Unfortunately, with current trends, a proportional 
increase of 72.4% in the number of people with diabetes in Malaysia is projected to 
occur by the year 2035. Thus, it is estimated that about 3,299,000 Malaysian diabetics 
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will be in need of life-time medical care in just two decades (Guariguata et al., 2014)—
which, to say the least, would be crippling for all governmental health service sectors. 
 
1.2 Clarifying ambiguous terminology: antidiabetic vs. antihyperglycemic and 
hypoglycemic 
Drugs used in diabetic care are usually described as antidiabetic, antihyperglycemic, 
and/or hypoglycemic. These terms seem to be often used by researchers 
interchangeably. However, subtle differences between these words may render such 
practice, on occasions, incorrect. Hence, it seems only warranted that a brief description 
be provided herein for accuracy purposes. 
As defined in Farlex Partner Medical Dictionary, the term “anti-diabetic” denotes an 
agent that reduces blood sugar. Though this might be the case for most antidiabetic 
drugs, it is not necessarily true for all. A more accurate definition may be found in 
Mosby's Medical Dictionary, in which an antidiabetic drug is rather defined as “any 
agent that prevents or relieves the symptoms of diabetes”, whereas an 
antihyperglycemic agent is described as “a substance or therapy that counteracts high 
levels of glucose in the blood”. Lastly, the term “hypoglycemic”, according to the 
definition of The American Heritage® Medical Dictionary, may apply to any agent that 
lowers the concentration of glucose in the blood. However, a drug might be labeled as 
“hypoglycemic” to indicate that it can induce a state of hypoglycemia, whereby BGLs 
fall below the normal range (2015).  
 
1.3 Trend to herbal therapy 
Several studies carried out in the field of diabetes research have shown that traditional 
medicines could provide better glycemic control than currently used conventional drugs 
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(Rates, 2001; Roja and Rao, 2000). Hence, plants possessing hypoglycemic activity 
may provide a useful source of new oral antidiabetic compounds for the development of 
pharmaceutical entities or as simple dietary adjuncts to existing therapies (Ogundipe et 
al., 2003). However, despite a lack of knowledge about most of the interactions between 
herbs and drugs, nearly 20% of patients taking prescription medication also take herbal 
and other dietary supplements (Kaufman et al., 2002; Gardiner et al., 2006). Though 
there are various approaches to reducing the ill effects of diabetes and its secondary 
complications, herbal medicines are still preferred due to less side effects and lower 
costs (Srivastava et al., 2012). The use of herbs from various corners of the world is 
being increasingly popularized in the modern world as adjuncts to conventional 
treatments for NIDDM, mainly by immigrants (Bailey et al., 1986). 
 
1.4 Gongronema latifolium Overview 
Gongronema latifolium Benth. (Apocyanaceae) (GL) is commonly grown in gardens in 
Calabar, Cross River State, Nigeria. Owing to its extensive presence in the tropical and 
the subtropical regions of Africa, GL has long been an integral part of the African 
traditional medicine. It has been used for a variety of medical conditions, such as 
hypertension, diabetes mellitus, malaria, mental, intestinal disorders (Ekong et al., 2014; 
Ugochukwu et al., 2003), intestinal worms, cough, dysentery, and dyspepsia (Iwu, 
2014). GL extracts have anti-inflammatory (Morebise et al., 2002), antifungal (Nwosu 
and Okafor, 1995), and moderate anti-laxative effects (Gamaniel and Akah, 1996). 
Overall, GL’s beneficial properties have been well documented, with a focus on it 
antidiabetic use (Eze and Nwanguma, 2012). It has also been commercially utilized as a 
substitute for commercial hops in large-scale beer production operations (Adenuga et 
al., 2010). Recently in the United States, it has been integrated into a DM Tea blend 
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claimed to maintain healthy BGLs (Akpaso et al., 2011) by Neimeth Pharmaceuticals 
(Iwu, 2014). Early reports justified GL antidiabetic use based on its antioxidant 
potential (Ugochukwu and Babady, 2002) and glucose lowering effect (Ugochukwu and 
Babady, 2003). However, over a decade after these preliminary reports, GL use in the 
treatment of DM, its mechanisms of action and potential long-term toxicity have 
remained vaguely understood. 
 
1.4.1 Morphological description  
GL is a perennial edible herbaceous shrub, with milky or less often, clear latex and soft 
flexible stems (Akpaso et al., 2011). Its flowers are mainly yellow (Edet et al., 2009) 
and, as seen in (Plate 1.1), the leaves are simple, smooth, opposite or occasionally 
whorled, very rarely alternate, usually without obvious stipules; and the margins are 
nearly always entire (Bingtao et al., 1977). It is a climbing plant with a soft and fibrous 
stem (Iwu, 2014). 
 
1.4.2 Taxonomy 
GL belongs to the kingdom Plantae and the Magnoliophyta phylum. It is of the 
Magnoliopsida class and the order of Gentianales. The family of GL is Apocyanaceae 
and it is of the Gongronema genus. The species is called Gongronema latifolium, and is 
commonly referred to as Bush Buck and Tafel Boom. Traditionally, GL has been called 
Utasi (Efiks, Ibibios and Quas tribes), Utazi (Igbos), Arokeke (Yorubas in Nigeria), as 
well as Aborode, akam, nsurogya (Ghana).  
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Plate 1.1: Gongronema latifolium Benth. (Apocyanaceae) courtesy of West African 
Plants.   
 
1.4.3 Chemical composition 
(Eneji et al., 2011) have reported that GL extracts contained a variety of phytochemical 
compounds, including alkaloids, saponins, tannins, flavonoids, and glycosides. 
Furthermore, different part of GL contain some phytochemicals like B-sistosterol, 
lupenyl esters, pregnane ester, and essential oils (Ekundayo, 1980; Morebise et al., 
2002). It is believed that these phytochemicals in GL can influence cellular proteins 
with enzymatic activities (Eze and Nwanguma, 2012). 
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1.4.4 GL use in DM treatment 
GL leaves, which are distinctly bitter (Eze and Nwanguma, 2012), were cooked as a 
vegetable soup and eaten as such for diabetes (Ogundipe et al., 2003). In some African 
cultures it is utilized as a spice for pancreas-related ailments (Okafor, 1999). A handful 
of studies have shown that GL possesses a considerable antihyperglycemic effect in 
animal diabetic models and in human subjects (Ejike et al., 2013). Yet, like most of the 
medicinal plants which have been identified in the recent decades, there is a lack of data 
on GL antidiabetic use, chronic and subchronic toxicity, dosing, and mechanisms of 
action. (Ugochukwu and Babady, 2003) argued that GL had an insulin-like activity. 
(Adebajo et al., 2012) reported that it acted by increasing insulin release. Meanwhile, 
(Ogbu et al., 2013) concluded that it attenuated blood glucose excursions partly by 
delaying gastric emptying. 
 
1.5 Problem statement 
The prevalence of DM is on the rise in South East Asia, particularly in Malaysia. 
Available DM drug classes vary in efficacy and method of administration. They often 
cause a spectrum of side effects, including weight gain, hypoglycemia and increased 
risk of mortality. Most are costly and have poor safety profiles. Natural alternatives like 
antidiabetic herbs can have similar capabilities and less adverse effects and/or cost. 
Several reports on GL have confirmed the validity of its traditional use in Africa in the 
treatment of DM. This suggests that GL might be beneficial and may make for a source 
of antidiabetic medication, or that it may work to commemorate the effects of 
antidiabetic drugs as an adjunct or a supplement. Hence, due to existing problems with 
currently available antidiabetic drugs, as well as a global trend towards herbal medicine, 
it was decided that it was of interest to look into GL further for potential therapeutic 
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agents. Studies have, in the recent years, managed to demonstrate its antioxidant 
potential and glucose lowering effect. However, GL use in the treatment of DM, its 
mechanisms of action and long-term toxicity remain vaguely understood. Hence, this 
study assessed GL blood glucose lowering activity, anti-diabetic mechanisms of action 
and sub-chronic toxicity using in vitro techniques and rat models.  
 
1.6 Tested hypothesis 
A soxhlet ethanolic extract of GL, GLES, retains a significant antihyperglycemic 
activity and produces structural recovery on the level of the pancreas. It can delay the 
transport of glucose via the intestinal wall and act as an insulin sensitizer. Furthermore, 
it has a good safety profile and does not cause systemic toxicity. 
  
1.7 Study objectives  
Main objective of the study: 
 To investigate the antihyperglycemic/antidiabetic activity of Nigerian Gongronema 
latifolium ethanolic extract in normal and chemically-induced (by STZ) diabetic 
rats. 
Secondary objectives: 
1) To assess the effects of Gongronema latfolium ethanolic extract on pancreatic 
Langerhans islets.                     
3) To investigate the mechanism(s) of action of Gongronema latifolium extract by 
examining its effect on intestinal glucose absorption and glucose uptake by 
isolated body tissues. 
4) To determine the safety of oral sub-chronic (90 days) exposure to Gongronema 
latifolium extract in Sprauge-Dawely rats of both sexes. 
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5) To make recommendations based on in vivo/in vitro antidiabetic and toxicity 
results to provide researchers and health care professionals with the safe and 
effective levels of the doses of GL ethanolic extract. 
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CHAPTER TWO: GENERAL METHODOLOGY 
 
2.1 Plant material 
Gongronema latifolium Benth (Apocynaceae) (GL), locally known as Utazi or Arokeke, 
was collected as whole plant from Yakkur, Cross River State, Nigeria at the following 
GPS coordinates (6
ₒ 08’17.35”N 8ₒ 41’15.54”E elev 420 ft) under the supervision of the 
Department of Biochemistry at the University of Calabar. Authentication was carried on 
by Pastor Frank, a botanist in the Department of Botany, and voucher specimen 
(ERU/2011/718) was deposited at the same department. The leaves were plucked of the 
twigs, washed with tap water and dried in the shade. The dried leaves were ground into 
powder. The powder was placed into a properly packaged courier to arrive at the 
Department of Pharmacology, Universiti Sains Malaysia via courier within 7 days. 
Upon receipt of the powder, it was placed at 4 ⁰C for further use. The plant name was 
verified by checking with www.theplantlist.org (website accessed on 16
th
 of September 
2015). 
 
2.2 Preparation of plant extract 
Upon receipt, 400 g of the powdered dried GL were extracted in ethanol using Soxhlet 
apparatus at 40-60 °C in ratio of 1:5 to 1:10 of material : solvent (w/v) for three days. 
Anti-pumping silicon granules were added each day before the apparatus was turned on. 
The extract was filtered and concentrated to about 1/10 of its original volume in a rotary 
evaporator at 40 °C. Thereafter, the concentrate was freeze-dried to obtain dried extract. 
The totally dry extract, referred to as GLES, amounted to a yield of ~ 12% and was 
stored at 4 ºC until further use. 
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2.3 Experimental animals 
Male and female Sprague-Dawley (SD) rats were used over the course of the present 
research. The animals weighed initially between 180 g - 220 g (6-7 weeks old) and were 
obtained from the Animal Research and Service Centre, Main Campus, Universiti Sains 
Malaysia (USM), Penang. The rats were housed pair-wise under standard environmental 
conditions (temperature, 25 ± 5 ºC; relative humidity, 50 ± 5% and 12 h light/dark 
cycle) throughout the period of the experiments. Prior to experimentation, the animals 
were acclimatized to laboratory conditions for one week in the Animal Transit Room at 
the School of Pharmaceutical Sciences, USM. The animals were allowed free access to 
standard rat pellets (Gold Coin Feedmills, Butterworth, Penang, Malaysia) and tap water 
ad libitum. The toxicity study was carried out according to OECD guidline 408 
(Murbach et al., 2014; OECD, 1998) and US FDA Redbook 2000, IV.C.4.a (90-day 
study) (FDA, 2003). Care and handling of study animals were performed according to 
the guidelines set by the WHO (World Health Organization, Geneva, Switzerland) with 
consideration to the principles of the Hungarian Act 2011 CLVIII (modification of 
Hungarian Act 1998 XXVIII) regulating animal protection. The institutional Animal 
Ethics Committee at Universiti Sains Malaysia approved the research [Approval 
number: USM/Animal Ethics Approval/2013/(90)(509)]. 
 
2.4 Induction of diabetes 
Diabetes was induced by a single intraperitoneal (IP) injection of streptozotocin (STZ) 
(Sigma-Aldrich, St. Louis, MO, USA) at a dose of (55 mg/kg) to rats fasted for 12 
hours. The injection solution was freshly prepared by reconstituting STZ in cold normal 
saline. The diabetic condition of the animals was confirmed 72 hours after the STZ 
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injection through measurement of the fasting blood glucose level (FBG) using the One 
Touch Glucometer (Accu-Chek Performa, Roche Diagnostics, Mannheim, Germany) 
via a single puncture of the tail vein. Only diabetic rats with FBG within 15.0-20.0 
mMol/L (270-360 mg/dl) were included in the study. 
 
2.5 Preparation of metformin for oral dosing 
Metformin 500 mg tablet (Glucophage
®
, Bristol-Myers Squibb, New York, USA) was 
grinded in a suitable amount of distilled water using a mortar and a pestle followed by 
ultra-sonication (UC-10 Ultrasonic Cleaner, Jeiotech, Seoul, Korea) for 15 min at 37 ⁰C. 
The amount of water used and the desired concentration of the solution were calculated 
for an administration volume of 10 ml/kg b.w. in all of the treated rat groups. 
  
2.6 Statistical analysis 
Data obtained from the male and female treatment groups were compared separately. 
The statistical comparison aimed at determining whether the differences observed 
between the treatment groups and the control resulted from GL consumption. Results 
were expressed as the mean ± SEM. Graphs were drawn and data was typed into 
Microsoft Excel 2007 (Microsoft Corp., Redmond, WA). Statistical analysis was 
performed using version 21 of the IBM-SPSS statistical program (IBM Corp., Armonk, 
NY). Normal distribution of the data was confirmed using the relevant tool in the same 
software program. One-way ANOVA was used followed by Dunnett’s Test as a Post 
Hoc Test for parametric multiple comparisons between the control and the treatment 
groups. Pre-treatment and post-treatment comparisons were performed using the paired 
t-test. Differences were considered significant when the P value was less than 0.05.  
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2.6 Flow chart of study protocols 
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CHAPTER THREE: ANTIDIABETIC STUDY OF GONGRONEMA 
LATIFOLIUM 
 
3.1 Background 
Diabetes Mellitus (DM) refers to a medical condition marked by hyperglycemia 
due to loss of control over blood glucose homeostasis. Diabetes Mellitus is a major 
cause of death worldwide. As projected in 2013 by the World Health Organization 
(WHO), DM is expected to become the 7th leading cause of death in 2030. There are 
two types of Diabetes: Type I, which is more severe, describes a condition in which 
insulin secretion is completely absent due to immune destruction of pancreatic β-cells 
(i.e., Insulin-Dependent Diabetes Mellitus: IDDM), whereas Type II describes a 
condition in which bodily cells (other than neurons) become irresponsive to insulin (i.e., 
Non-Insulin-Dependent Diabetes Mellitus: NIDDM). According to the Malaysian 
Ministry of Health, there were more than 3 million Malaysians with DM in 2011 (Amal 
et al., 2011). It is very alarming considering the fact that 80% of diabetes deaths occur 
in low- and middle-income countries, and that the number of diabetics in the Western 
Pacific Region is expected to double within twenty years from now (WHO). Treatment 
for NIDDM, a multifactorial disease, includes many different, expensive combinations 
of drugs whose use is restricted by their pharmacokinetic properties, secondary failure 
rates, and many accompanying side effects (Hammouda and Amer, 1966), which 
include weight gain, increased risk of hypoglycemia, and increased risk of mortality 
(Rang and Dale, 1999). Thus, there is a grave need for natural drugs that have similar 
efficacy but do not have such adverse effects or cost.  
Gongronema latifolium Benth (Apocynaceae) is a perennial edible shrub with a 
soft stem. Its leaves are usually simple, opposite or occasionally whorled with no clear 
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stipules (Bingtao et al., 1977). It is widely used in the West African sub region for a 
number of medicinal and nutritional purposes (Akpaso et al., 2011) and to treat a variety 
of ailments, such as hypertension, diabetes mellitus, malaria, mental and intestinal 
disorders (Ekong et al., 2014; Ugochukwu et al., 2003). Traditionally, the leaves of GL 
were cooked as a vegetable soup and eaten as such for diabetes (Ogundipe et al., 2003) 
and in some African cultures it is utilized as a spice to support the pancreas (Okafor, 
1999). Recently in the United States, it has been integrated into a DM Tea blend which 
is claimed to maintain healthy glycemia (Akpaso et al., 2011). Previous reports 
(Ugochukwu et al., 2003; Ugochukwu and Cobourne, 2003), justified its traditional use 
for DM based on its effect in ameliorating the oxidative stress which accompanies DM 
and which underlies many of the complications of diabetes. Although more recent 
reports (Akpaso et al., 2011; Ejike et al., 2013; Nnodim et al., 2012) have confirmed 
that GL possesses antihyperglycemic activity, its use in the treatment of DM, as well as 
its mechanisms of action, remain vaguely understood. While (Ugochukwu and Babady, 
2003) attributed an insulin-like activity to GL ethanolic extract, (Adebajo et al., 2012) 
reported that the extract acted by increasing insulin release.  
This study evaluates the effect of GL leaf-extract on BGLs upon acute and sub-
chronic administration in diabetic rats. Furthermore, it examines the effect of sub-
chronic administration of GL extract on serum lipid profile, kidney function indices and 
the insulin-secreting cells (Langerhans islets). It explores for the first time, the effect of 
GL extract on in vitro insulin and glucose transduction in isolated rat abdominal muscle 
and jejunum. Lastly, a profiling of the chemical composition of the extract is done with 
the use of Gas Chromatography-Mass Spectroscopy (GC-MS).    
 
 
